Updates to the Transparency Directive have been put forward by the European Commission to speed national decisions on drug prices and reimbursement.
These decisions, which have taken 180 days to date, should be made for new medicines in no more than 120 days, and for generics, within 30 days.
The time restrictions, which are currently often missed by Member States, will be enforced more strongly.
The plans could reduce health costs, the Commission suggests, by bringing generic products to market earlier.
The update will replace the 1989 Directive, which has not kept pace with increases in the complexity of pricing and reimbursement in Member States.